MX2020008860A - Lisinas plyss2 modificadas y sus usos. - Google Patents
Lisinas plyss2 modificadas y sus usos.Info
- Publication number
- MX2020008860A MX2020008860A MX2020008860A MX2020008860A MX2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- methods
- modified lysin
- disclosed
- modified
- Prior art date
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 150000001413 amino acids Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 241000192125 Firmicutes Species 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 241000894007 species Species 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24075—Lysostaphin (3.4.24.75)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635515P | 2018-02-26 | 2018-02-26 | |
| PCT/US2019/019638 WO2019165454A1 (en) | 2018-02-26 | 2019-02-26 | Modified plyss2 lysins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008860A true MX2020008860A (es) | 2020-12-10 |
Family
ID=67687985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008860A MX2020008860A (es) | 2018-02-26 | 2019-02-26 | Lisinas plyss2 modificadas y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210032294A1 (enExample) |
| EP (1) | EP3758738A4 (enExample) |
| JP (1) | JP2021513865A (enExample) |
| KR (1) | KR20200124724A (enExample) |
| CN (1) | CN112118861A (enExample) |
| AU (1) | AU2019224160A1 (enExample) |
| BR (1) | BR112020017219A2 (enExample) |
| CA (1) | CA3092109A1 (enExample) |
| IL (1) | IL276807A (enExample) |
| MX (1) | MX2020008860A (enExample) |
| RU (1) | RU2020128276A (enExample) |
| WO (1) | WO2019165454A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980049A4 (en) * | 2019-04-11 | 2023-07-19 | Contrafect Corporation | METHOD OF TREATMENT AND PREVENTION OF BONE AND JOINT INFECTIONS |
| WO2021236636A1 (en) * | 2020-05-19 | 2021-11-25 | Contrafect Corporation | MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA |
| WO2023049747A1 (en) * | 2021-09-22 | 2023-03-30 | Elanco Us Inc. | Streptococcus suis lytic enzyme compositions and methods of use thereof |
| WO2023081691A1 (en) * | 2021-11-04 | 2023-05-11 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| CN115851689A (zh) * | 2022-08-09 | 2023-03-28 | 中南民族大学 | 一种嵌合裂解酶PlySs2E-V12C及其应用、重组质粒和重组菌株 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2833409A1 (en) * | 2011-04-21 | 2012-10-26 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| CN103703127A (zh) * | 2011-05-04 | 2014-04-02 | 迈克瑞欧斯人体健康有限公司 | 一种多肽 |
| KR20210121313A (ko) * | 2012-05-09 | 2021-10-07 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| KR20200023521A (ko) * | 2012-05-09 | 2020-03-04 | 콘트라펙트 코포레이션 | 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 |
| CN104073478A (zh) * | 2014-06-13 | 2014-10-01 | 上海交通大学 | 杀灭革兰氏阳性菌的酶抗生素及其制备、用途 |
| CN104211781A (zh) * | 2014-09-04 | 2014-12-17 | 北京纳百景弈生物科技有限公司 | 金黄色葡萄球菌裂解蛋白的制备方法及其应用 |
| KR20190004799A (ko) * | 2016-05-12 | 2019-01-14 | 콘트라펙트 코포레이션 | 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법 |
-
2019
- 2019-02-26 KR KR1020207027681A patent/KR20200124724A/ko not_active Ceased
- 2019-02-26 BR BR112020017219-7A patent/BR112020017219A2/pt not_active IP Right Cessation
- 2019-02-26 EP EP19757130.0A patent/EP3758738A4/en active Pending
- 2019-02-26 AU AU2019224160A patent/AU2019224160A1/en not_active Abandoned
- 2019-02-26 MX MX2020008860A patent/MX2020008860A/es unknown
- 2019-02-26 WO PCT/US2019/019638 patent/WO2019165454A1/en not_active Ceased
- 2019-02-26 US US16/975,321 patent/US20210032294A1/en not_active Abandoned
- 2019-02-26 CN CN201980027962.7A patent/CN112118861A/zh active Pending
- 2019-02-26 JP JP2020544642A patent/JP2021513865A/ja active Pending
- 2019-02-26 RU RU2020128276A patent/RU2020128276A/ru unknown
- 2019-02-26 CA CA3092109A patent/CA3092109A1/en active Pending
-
2020
- 2020-08-19 IL IL276807A patent/IL276807A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019165454A1 (en) | 2019-08-29 |
| BR112020017219A2 (pt) | 2020-12-22 |
| KR20200124724A (ko) | 2020-11-03 |
| CN112118861A (zh) | 2020-12-22 |
| EP3758738A4 (en) | 2021-12-08 |
| IL276807A (en) | 2020-10-29 |
| EP3758738A1 (en) | 2021-01-06 |
| JP2021513865A (ja) | 2021-06-03 |
| CA3092109A1 (en) | 2019-08-29 |
| US20210032294A1 (en) | 2021-02-04 |
| AU2019224160A1 (en) | 2020-09-10 |
| RU2020128276A (ru) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008860A (es) | Lisinas plyss2 modificadas y sus usos. | |
| US11690899B2 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
| MX2021015563A (es) | Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes. | |
| Dusane et al. | Disruption of microbial biofilms by an extracellular protein isolated from epibiotic tropical marine strain of Bacillus licheniformis | |
| Perumal et al. | Purification and characterization of a bacteriocin, BacBS2, produced by Bacillus velezensis BS2 isolated from Meongge Jeotgal | |
| JP2021508235A5 (enExample) | ||
| AR047347A1 (es) | Miembros de la familia cry9 de bacillus | |
| KR101796279B1 (ko) | 새로운 호스트 바인딩 도메인을 갖는 포도상구균 박테리오파지 SA11 유래의 엔도라이신 LysSA11 및 이를 포함하는 세균 사멸용 조성물 | |
| MX2020010071A (es) | Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas. | |
| KR101985663B1 (ko) | 꽃게 유래의 항균 펩타이드 및 그의 용도 | |
| CN107312080B (zh) | 一种来源于gsdmd蛋白的抗菌肽及其应用 | |
| Lee et al. | Antimicrobial effect of bacteriocin KU24 produced by Lactococcus lactis KU24 against methicillin‐resistant Staphylococcus aureus | |
| BR112021018461A8 (pt) | Proteínas de fusão, bactérias recombinantes e fragmentos de exospório para saúde da planta | |
| Keska et al. | Antimicrobial peptides of meat origin-an in silico and in vitro analysis | |
| Francis et al. | Antimicrobial peptides: features and modes of action | |
| MX2020008677A (es) | Novedoso bacteriofago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg. | |
| MX2023011235A (es) | Construcciones de amurinas, lisinas y peptido antimicrobiano de lisina (amp) activas contra bacterias gram negativas. | |
| WO2005021575A3 (en) | Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties | |
| ES2382466T3 (es) | Péptidos inductores de bacteriocinas | |
| Mohd-Yusoff et al. | Trypsin inhibitor isolated from Streptomyces misionensis UMS1 has anti-bacterial activities and activates α-amylase | |
| CN106754849B (zh) | 一种多功能裂解酶及其制备方法和应用 | |
| MX2024009675A (es) | Gen modificado para cultivo mas eficiente de pepino. | |
| Kim et al. | Characterization of the antimicrobial substances produced by Nibribacter radioresistens | |
| US20100151097A1 (en) | Optimization of colicin production | |
| CN116732013B (zh) | 具有抗菌活性的细胞壁降解酶 |